Literature DB >> 17909025

Roles for the stem cell associated intermediate filament Nestin in prostate cancer migration and metastasis.

Wolfram Kleeberger1, G Steven Bova, Matthew E Nielsen, Mehsati Herawi, Ai-Ying Chuang, Jonathan I Epstein, David M Berman.   

Abstract

The intermediate filament protein Nestin identifies stem/progenitor cells in adult tissues, but the function of Nestin is poorly understood. We investigated Nestin expression and function in common lethal cancers. Nestin mRNA was detected in cell lines from small cell lung, and breast cancers, and particularly elevated in cell lines derived from prostate cancer metastases. Whereas the androgen-independent lines PC3, 22RV1, and DU145 all expressed Nestin transcripts under standard culture conditions, the androgen-dependent line LnCaP expressed Nestin only on androgen withdrawal. We confirmed associations of Nestin expression, androgen withdrawal, and metastatic potential by immunohistochemical analysis of samples from 254 prostate cancer patients. Cytoplasmic Nestin protein was readily identifiable in prostate cancer cells from 75% of patients with lethal androgen-independent disease, even in cancer sampled from the prostate itself. However, Nestin expression was undetectable in localized androgen-deprived tumors and in metastases without prior androgen deprivation. To address its function, we reduced Nestin levels with short hairpin RNAs, markedly inhibiting in vitro migration and invasion in prostate cancer cells but leaving cell growth intact. Nestin knockdown also diminished metastases 5-fold compared with controls despite uncompromised tumorigenicity at the site of inoculation. These results specify a function for Nestin in cell motility and identify a novel pathway for prostate cancer metastasis. Activity of this pathway may be selected by the extraprostatic environment or, as supported by our data, may originate within the prostate after androgen deprivation. Further dissection of this novel Nestin migration pathway may lead to strategies to prevent and neutralize metastatic spread.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17909025      PMCID: PMC3072059          DOI: 10.1158/0008-5472.CAN-07-0806

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  42 in total

1.  A high molecular weight intermediate filament-associated protein in BHK-21 cells is nestin, a type VI intermediate filament protein. Limited co-assembly in vitro to form heteropolymers with type III vimentin and type IV alpha-internexin.

Authors:  P M Steinert; Y H Chou; V Prahlad; D A Parry; L N Marekov; K C Wu; S I Jang; R D Goldman
Journal:  J Biol Chem       Date:  1999-04-02       Impact factor: 5.157

Review 2.  Tissue repair and stem cell renewal in carcinogenesis.

Authors:  Philip A Beachy; Sunil S Karhadkar; David M Berman
Journal:  Nature       Date:  2004-11-18       Impact factor: 49.962

3.  Class VI intermediate filament protein nestin is induced during activation of rat hepatic stellate cells.

Authors:  T Niki; M Pekny; K Hellemans; P D Bleser; K V Berg; F Vaeyens; E Quartier; F Schuit; A Geerts
Journal:  Hepatology       Date:  1999-02       Impact factor: 17.425

4.  Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy.

Authors:  Stephen J Freedland; Elizabeth B Humphreys; Leslie A Mangold; Mario Eisenberger; Frederick J Dorey; Patrick C Walsh; Alan W Partin
Journal:  JAMA       Date:  2005-07-27       Impact factor: 56.272

Review 5.  Cell migration in tumors.

Authors:  Hideki Yamaguchi; Jeffrey Wyckoff; John Condeelis
Journal:  Curr Opin Cell Biol       Date:  2005-10       Impact factor: 8.382

6.  Three-dimensional ultrasound biomicroscopy for xenograft growth analysis.

Authors:  Alison M Y Cheung; Allison S Brown; Lauren A Hastie; Viviene Cucevic; Marcia Roy; James C Lacefield; Aaron Fenster; F Stuart Foster
Journal:  Ultrasound Med Biol       Date:  2005-06       Impact factor: 2.998

7.  Nestin expression by newly formed human blood vessels.

Authors:  J Mokrý; D Cízková; S Filip; J Ehrmann; J Osterreicher; Z Kolár; D English
Journal:  Stem Cells Dev       Date:  2004-12       Impact factor: 3.272

Review 8.  The role of inflammation in the pathogenesis of prostate cancer.

Authors:  William G Nelson; Angelo M De Marzo; Theodore L DeWeese; William B Isaacs
Journal:  J Urol       Date:  2004-11       Impact factor: 7.450

9.  Pancreatic epithelial plasticity mediated by acinar cell transdifferentiation and generation of nestin-positive intermediates.

Authors:  Anna L Means; Ingrid M Meszoely; Kazufumi Suzuki; Yoshiharu Miyamoto; Anil K Rustgi; Robert J Coffey; Christopher V E Wright; Doris A Stoffers; Steven D Leach
Journal:  Development       Date:  2005-07-14       Impact factor: 6.868

Review 10.  Emergence of metastatic hormone-refractory disease in prostate cancer after anti-androgen therapy.

Authors:  Edmund Chun Yu Lee; Martin P R Tenniswood
Journal:  J Cell Biochem       Date:  2004-03-01       Impact factor: 4.429

View more
  79 in total

Review 1.  Nestin in gastrointestinal and other cancers: effects on cells and tumor angiogenesis.

Authors:  Toshiyuki Ishiwata; Yoko Matsuda; Zenya Naito
Journal:  World J Gastroenterol       Date:  2011-01-28       Impact factor: 5.742

2.  An EGFR-ERK-SOX9 signaling cascade links urothelial development and regeneration to cancer.

Authors:  Shizhang Ling; Xiaofei Chang; Luciana Schultz; Thomas K Lee; Alcides Chaux; Luigi Marchionni; George J Netto; David Sidransky; David M Berman
Journal:  Cancer Res       Date:  2011-04-21       Impact factor: 12.701

3.  Androgen-Regulated SPARCL1 in the Tumor Microenvironment Inhibits Metastatic Progression.

Authors:  Paula J Hurley; Robert M Hughes; Brian W Simons; Jessie Huang; Rebecca M Miller; Brian Shinder; Michael C Haffner; David Esopi; Yasunori Kimura; Javaneh Jabbari; Ashley E Ross; Nicholas Erho; Ismael A Vergara; Sheila F Faraj; Elai Davicioni; George J Netto; Srinivasan Yegnasubramanian; Steven S An; Edward M Schaeffer
Journal:  Cancer Res       Date:  2015-08-20       Impact factor: 12.701

4.  KU675, a Concomitant Heat-Shock Protein Inhibitor of Hsp90 and Hsc70 that Manifests Isoform Selectivity for Hsp90α in Prostate Cancer Cells.

Authors:  Weiya Liu; George A Vielhauer; Jeffrey M Holzbeierlein; Huiping Zhao; Suman Ghosh; Douglas Brown; Eugene Lee; Brian S J Blagg
Journal:  Mol Pharmacol       Date:  2015-05-04       Impact factor: 4.436

5.  Nestin expression correlates with nerve and retroperitoneal tissue invasion in pancreatic cancer.

Authors:  Masao Kawamoto; Toshiyuki Ishiwata; Kazumitsu Cho; Eiji Uchida; Murray Korc; Zenya Naito; Takashi Tajiri
Journal:  Hum Pathol       Date:  2008-09-16       Impact factor: 3.466

6.  Pancreatic cancer with Nest-in tendencies.

Authors:  Sophia L Maund; Scott D Cramer
Journal:  Cancer Biol Ther       Date:  2011-03-15       Impact factor: 4.742

7.  Global transcriptomic analysis of model human cell lines exposed to surface-modified gold nanoparticles: the effect of surface chemistry.

Authors:  E M Grzincic; J A Yang; J Drnevich; P Falagan-Lotsch; C J Murphy
Journal:  Nanoscale       Date:  2015-01-28       Impact factor: 7.790

8.  Immunohistochemical and electronmicroscopic features of mesenchymal-to-epithelial transition in human developing, postnatal and nephrotic podocytes.

Authors:  Natalija Filipovic; Katarina Vukojevic; Ivana Bocina; Marijan Saraga; Merica Glavina Durdov; Boris Kablar; Mirna Saraga-Babic
Journal:  Histochem Cell Biol       Date:  2016-10-01       Impact factor: 4.304

9.  Mammary tumors initiated by constitutive Cdk2 activation contain an invasive basal-like component.

Authors:  Patrick E Corsino; Bradley J Davis; Peter H Nørgaard; Nicole N Teoh Parker; Mary Law; William Dunn; Brian K Law
Journal:  Neoplasia       Date:  2008-11       Impact factor: 5.715

10.  Endothelial cells enhance prostate cancer metastasis via IL-6→androgen receptor→TGF-β→MMP-9 signals.

Authors:  Xiaohai Wang; Soo Ok Lee; Shujie Xia; Qi Jiang; Jie Luo; Lei Li; Shuyuan Yeh; Chawnshang Chang
Journal:  Mol Cancer Ther       Date:  2013-03-27       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.